Cell and Gene Therapy Market Size Worth USD 6.57 Million By 2027

Cell and gene therapy have made significant strides in medical science and have the potential to completely change how many diseases are treated. These treatments use cells or genes to repair or improve the function of the body's damaged or defective cells. Recent technological developments, an increase in research and development activities, and a rising desire for personalised medicine have all contributed to the market's impressive expansion. The promise to offer curative therapies for diseases that were previously incurable or challenging to treat is one of the main factors driving the market for cell and gene therapy. These treatments have a lot of potential for treating cancer, autoimmune diseases, degenerative ailments, and genetic disorders. The capacity to alter genes or swap out damaged cells opens up new possibilities for focused and precise therapeutic strategies. With cell and gene therapies, patients who have tried all traditional therapy methods now have fresh hope for better results.

The expansion of the industry for cell and gene therapy has also been greatly aided by government initiatives and regulatory backing. Global regulatory organisations have adopted mechanisms to speed up the research and approval of these medicines because they recognise their promise. To hasten the development and approval of these novel therapies, the U.S. Food and Drug Administration (FDA) has created the Regenerative Medicine Advanced Therapy (RMAT) designation. Such measures have stimulated investments and market expansion while fostering an atmosphere that is favourable for the commercialization of cell and gene therapies. The market for cell and gene therapy, however, nevertheless confronts substantial obstacles and limitations. The high price tag attached to these medicines is one of the main obstacles. Cell and gene treatments are developed and produced using sophisticated methods that call for specialised infrastructure and knowledge. Significant production expenses result from this, which are frequently passed on to patients and healthcare systems. Additionally, it is difficult for patients to receive these therapies because the payment environment is continually changing. For cell and gene therapies to be widely used and to experience economic success, it will be essential to address these cost-related challenges and develop reimbursement mechanisms.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/27

Despite these obstacles, a number of growth factors are driving the market for cell and gene therapy ahead. The manufacture of these medicines is becoming more effective and scalable thanks to technological developments in gene editing, viral vectors, and cell culture methods. Furthermore, the demand for novel treatment alternatives is being fueled by the rising frequency of chronic diseases including cancer and cardiovascular conditions. The development and widespread use of cell and gene therapies are further fueled by the increased emphasis on precision medicine and personalised treatments since they provide individualised care based on a person's genetic profile. Government statistics demonstrate the market for cell and gene therapy's enormous growth and potential. In 2020, there were over 1,100 active clinical studies for cell and gene treatments across the globe, encompassing a range of disease areas, according to a report from the Alliance for Regenerative Medicine. According to the research, there will be 26 licenced medications for cell and gene therapy in Europe and 17 products in the United States by the end of 2020. certain figures show how popular and well-liked certain treatments are becoming in the medical community.

Major Companies and Competitive Landscape:
The competitive landscape of the cell and gene therapy market is dynamic and evolving, with several companies vying for market share and striving to lead in this innovative field. The market is characterized by a mix of established pharmaceutical companies, emerging biotech firms, and academic institutions that are actively engaged in research and development activities. Key participants include Spark Therapeutics LLC, Novartis AG, Gilead Sciences Inc., Bluebird Bio, GlaxoSmithKline, Celgene Corporation, Shire PLC, Sangamo Biosciences, Voyager Therapeutics, and Dimension Therapeutics, among others.

Gilead Sciences, Inc.: Gilead Sciences is another major player in the cell and gene therapy market. They acquired Kite Pharma in 2017, gaining access to Yescarta, an FDA-approved CAR-T therapy for certain types of non-Hodgkin lymphoma. Gilead Sciences continues to focus on developing innovative therapies for cancer and other diseases using cell and gene therapy approaches.

bluebird bio: bluebird bio is a biotech company dedicated to developing gene therapies for severe genetic diseases and cancer. Their product Zynteglo, an investigational gene therapy for transfusion-dependent beta-thalassemia, received conditional marketing authorization in Europe. The company is also actively pursuing gene editing technologies and has collaborations with various partners to advance their pipeline.

Spark Therapeutics: Spark Therapeutics, now part of Roche, has made significant contributions to the field of gene therapy. They gained FDA approval for Luxturna, a gene therapy for inherited retinal disease, making it the first FDA-approved gene therapy for a genetic disease in the United States. Spark Therapeutics continues to explore gene therapies for various genetic disorders.

Sangamo Therapeutics: Sangamo Therapeutics is a biotech company that focuses on developing genomic medicines using their proprietary gene editing platform, zinc finger nuclease (ZFN) technology. They have multiple ongoing clinical programs targeting genetic diseases and cancer, utilizing both gene editing and gene therapy approaches.

Editas Medicine: Editas Medicine is at the forefront of CRISPR-based gene editing technology. They are developing innovative therapies to treat genetic diseases, including inherited retinal diseases and sickle cell disease. The company has partnerships with pharmaceutical giants like Allergan and Bristol Myers Squibb to accelerate their research and development efforts.

Apart from these key players, there are numerous other companies and academic institutions actively involved in the development of cell and gene therapies. Many of them focus on specific therapeutic areas or employ different gene editing technologies, contributing to the competitive landscape. Collaboration and partnerships between pharmaceutical companies, biotech firms, and academic institutions are common, aiming to leverage collective expertise and resources to advance the field. The competitive landscape is expected to remain intense as more companies invest in cell and gene therapy research and development. Factors such as intellectual property rights, manufacturing capabilities, regulatory approvals, and clinical trial success will continue to shape the competitive dynamics within the market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/27

Segmentation Insights for Cell and Gene Therapy:
The cell and gene therapy market is expected to witness substantial revenue growth across various indications from 2017 to 2027. Acute Lymphoblastic Leukemia (ALL) is projected to be one of the leading indications, with a significant revenue contribution. The advancements in CAR-T cell therapies have shown promising results in treating ALL, driving the market's growth in this segment. Inherited Retinal Disease is another indication poised for remarkable revenue growth during the forecast period. Gene therapies targeting genetic mutations causing retinal diseases have shown great potential in restoring vision and improving patients' quality of life. This has led to a surge in research and development efforts, paving the way for substantial revenue generation.

Large B-Cell Lymphoma is expected to contribute significantly to the cell and gene therapy market. The development of CAR-T therapies targeting CD19-expressing lymphomas has demonstrated impressive efficacy in patients with relapsed or refractory disease. As a result, the market for cell and gene therapies in this indication is anticipated to experience substantial growth.

Other indications not specifically mentioned above are also expected to contribute to the overall revenue of the cell and gene therapy market. These may include various genetic disorders, cancer types, autoimmune diseases, and degenerative conditions. The market's expansive nature allows for the exploration and development of innovative therapies across a wide range of diseases and conditions. In terms of vectors used for delivering cell and gene therapies, several options show potential revenue growth. Lentivirus, adeno-associated virus (AAV), retrovirus & gammaretrovirus, modified herpes simplex virus, adenovirus, and non-viral plasmid vectors are among the prominent vectors in the market. These vectors offer different advantages and are suited for specific therapeutic applications, contributing to the overall revenue generated by the cell and gene therapy market.

Geographically, North America is expected to dominate the cell and gene therapy market, with the United States and Canada being key contributors to revenue. The region has a robust infrastructure, favorable regulatory environment, and significant investments in research and development, facilitating market growth. In Europe, countries like Germany, the UK, France, and BENELUX (Belgium, the Netherlands, and Luxembourg) are expected to contribute substantially to the market revenue. The region has witnessed significant advancements in cell and gene therapy research, along with supportive regulations and healthcare infrastructure.
Asia Pacific, particularly China, Japan, and South Korea, is poised for considerable growth in the cell and gene therapy market. These countries have shown a rapid increase in research and development activities, investments, and supportive government initiatives to promote innovation in the field of cell and gene therapies. Latin America, led by Brazil, is also expected to witness market growth, driven by increased awareness, improved healthcare infrastructure, and growing investments in the field. Similarly, the Middle East and Africa (MEA) region, particularly Saudi Arabia and the UAE, are emerging as potential markets for cell and gene therapy, supported by advancements in healthcare infrastructure and rising healthcare expenditure. The cell and gene therapy market is expected to witness significant revenue growth across various indications, vector types, and geographic regions. Advancements in technology, supportive regulatory frameworks, and increasing investments in research and development are the key drivers propelling the market's expansion.

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/cell-and-gene-therapy-market

Related Reports are:
Polypropylene Compound Market @ https://www.prnewswire.co.uk/news-releases/polypropylene-compound-market-size-to-reach-usd-31-47-billion-in-2028-increasing-demand-for-pp-compounds-in-automotive-interiors-and-demand-for-materials-that-require-negligible-paint-processing-are-key-factors-driving-industry-demand-says--869439783.html

Advanced Prostheses and Exoskeletons Market @ https://prtimes.jp/main/html/rd/p/000000042.000082259.html

Virtual Diagnostics Market @ https://www.globenewswire.com/news-release/2020/12/10/2142721/0/en/Virtual-Diagnostics-Market-Size-To-Be-Worth-USD-1-512-2-Million-by-2027-Growing-at-a-CAGR-of-15-0-Emergen-Research.html

Natural Sweeteners Market @ https://www.globenewswire.com/news-release/2021/03/18/2195756/0/en/Natural-Sweeteners-Market-Size-to-Reach-USD-4-72-Billion-by-2028-Increasing-Prevalence-of-Obesity-and-Diabetes-are-Some-Key-Factors-Driving-Industry-Growth-says-Emergen-research.html

Sterilization Services Market @ https://www.prnewswire.co.uk/news-releases/sterilization-services-market--size-to-reach-usd-24-33-billion-in-2030--emergen-research-301722401.html

Metal Foam Market @ https://www.prnewswire.co.uk/news-releases/metal-foam-market-size-to-reach-usd-123-6-mn-in-2028-rising-demand-for-aluminum-foam-in-automotive-and-transportation-industries-owing-to-low-weight-high-strength-and-durability-are-key-factors-driving-industry-demand-says-emergen-research-816964107.html

Carbon Nanotube Market @ https://www.prnewswire.co.uk/news-releases/carbon-nanotube-market-size-to-reach-usd-3-027-4-million-in-2030-increasing-application-of-carbon-nanotubes-in-electric-vehicles-is-a-major-factor-driving-industry-demand-says-emergen-research-854191124.html

Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions.

This release was published on openPR.